Twist Bioscience: Lilly Deal and Forecast Upgrade Ignite Stock
Reading Time: 2 minutes
Cooperation with Eli Lilly: As the preferred data provider for the TuneLab platform, the company is strategically expanding its role in AI drug discovery. Revenue Record & Outlook: Q3 revenues climb by 23% to $118.38 million, prompting a significant upward revision of the 2026 forecast. Volume Accumulation: Despite slightly missing the EPS target, investors are heavily buying due to the improved gross margin of 52.8% and the AI boom. The US biotech company Twist Bioscience acts as a key player in the global megatrends of synthetic...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
